Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of antitumor immunity

Journal of Immunology

Volumn 164, Issue 2, 2000, Pages 698-704

  Martín Fontecha, Alfonso ^a,b   Moro, Monica ^b   Crosti, Maria Cristina ^b   Veglia, Fabrizio ^c   Casorati, Giulia ^b,c   Dellabona, Paolo ^b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Cancer Immunotherapy Gene Ther P   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOLOGY; CONTROLLED STUDY; HOST RESISTANCE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

EID: 0342632802     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.2.698     Document Type: Article

References (58)

1. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065.
2. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
3. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors [Published erratum appears in 1995 Immunity 2:204.]. Immunity 1:793.
4. Truneh, A., M. Reddy, P. Ryan, S. D. Lyn, C. Eichman, D. Couez, M. R. Hurle. R. P. Sekaly, D. Olive, and R. Sweet. 1996. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis. Mol. Immunol. 33:321.
5. Morton, P. A., X. T. Fu, J. A. Stewart, K. S. Giacoletto, S. L. White, C. E. Leysath, R. J. Evans, J. J. Shieh, and R. W. Karr. 1996. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). J. Immunol. 156:1047.
6. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
7. Caux, C., B. Vanbervliet, C. Massacrier, M. Azuma, K. Okumura, L. L. Lanier, and J. Banchereau. 1994. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 180: 1841.
8. Larsen, C. P., S. C. Ritchie, R. Hendrix, P. S. Linsley, K. S. Hathcock, R. J. Hodes, R. P. Lowry, and T. C. Pearson. 1994. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol. 152:5208.
9. Inaba, K., M. Witmer-Pack, M. Inaba, K. S. Hathcock, H. Sakuta, M. Azuma, H. Yagita, K. Okumura, P. S. Linsley, S. Ikehara, et al. 1994. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180:1849.
10. Kawamura, T., and M. Furue. 1995. Comparative analysis of B7-1 and B7-2 expression in Langerhans cells: differential regulation by T helper type 1 and T helper type 2 cytokines. Eur. J. Immunol. 25:1913.
11. Rugtveit, J., A. Bakka, and P. Brandtzaeg. 1997. Differential distribution of B7.1(Cd80) and B7.2(Cd86) costimulalory molecules on mucosal macrophage subsets in human inflammatory bowel disease (Ibd). Clin. Exp. Immunol. 110: 104.
12. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X. Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523.
13. Ranger, A. M., M. P. Das, V. K. Kuchroo, and L. H. Glimcher. 1996. B7-2 (CD86) is essential for the development of IL-4-producing T cells. Int. Immunol. 8:1549.
14. Rulifson, I. C., A. I. Sperling, P. E. Fields, F. W. Fitch, and J. A. Bluestone. 1997. CD28 costimulation promotes the production of Th2 cytokines. J. Immunol. 158: 658.
15. Subramanian, G., J. W. Kazura, E. Pearlman, X. Jia, I. Malhotra, and C. L. King. 1997. B7-2 requirement for helminth-induced granuloma formation and CD4 type 2 T helper cell cytokine expression. J. Immunol. 158:5914.
16. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
17. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
18. Racke, M. K., D. E. Scott, L. Quigley, G. S. Gray, R. Abe, C. H. June, and P. J. Perrin. 1995. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 96:2195.
19. Thompson, C. B. 1995. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation. Cell 81:979.
20. Bluestone, J. A. 1995. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555.
21. + T cells and induce similar patterns of cytokine secretion in vitro. Int. Immunol. 7:891.
22. Schweitzer, A. N., F. Borriello, R. C. Wong, A. K. Abbas, and A. H. Sharpe. 1997. Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. J. Immunol. 158:2713.
23. Chen, L., P. S. Linsley, and K. E. Hellstrom. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
24. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90:5687.
25. Yang, G., K. E. Hellstrom, I. Hellstrom, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
26. La Motte, R. N., M. A. Rubin, E. Barr, J. M. Leiden, J. A. Bluestone, and M. B. Mokyr. 1996. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol. Immunother. 42:161.
27. Martin-Fontecha, A., F. Cavallo, M. Bellone, S. Heltai, G. Iezzi, P. Tornaghi, N. Nabavi, G. Forni, P. Dellabona, and G. Casorati. 1996. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur. J. Immunol. 26:1851.
28. Matulonis, U., C. Dosiou, G. Freeman, C. Lamont, P. Mauch, L. M. Nadler, and J. D. Griffin. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126.
29. Gajewski, T. F., F. Fallarino, C. Uyttenhove, and T. Boon. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909.
30. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156:465.
31. Ohara, J., and W. E. Paul. 1985. Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature 315:333.
32. Landolfo, S., F. Cofano, M. Giovarelli, M. Prat, G. Cavallo, and G. Forni. 1985. Inhibition of interferon-γ may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science 229:176.
33. + T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation). Eur. J. Immunol. 24:859.
34. Cayeux, S., G. Richter, G. Noffz, B. Dorken, and T. Blankenstein. 1997. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol. 158:2834.
35. Ross, E. M. 1996. Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect. In The Pharmacological Basis of Therapeutics. J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, A. V. Goodman, and D. Gilman, eds. McGraw-Hill, New York.
36. Kariv, I., A. Truneh, and R. W. Sweet. 1996. Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function. J. Immunol. 157:29.
37. van der Merwe, P. A., D. L. Bodian, S. Daenke, P. Linsley, and S. J. Davis. 1997. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J. Exp. Med. 185:393.
38. Greene, J. L., G. M. Leytze, J. Emswiler, R. Peach, J. Bajorath, W. Cosand, and P. S. Linsley. 1996. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulalory interactions. J. Biol. Chem. 271: 26762.
39. Krummel, M. F., and J. P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533.
40. Walunas, T. L., C. Y. Bakker, and J. A. Bluestone. 1996. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183:2541.
41. Thompson, C. B., and J. P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity 7:445.
42. Bluestone, J. A. 1997. Is CTLA-4 a master switch for peripheral T cell tolerance? J. Immunol. 158:1989.
43. Khattri, R., J. A. Auger, M. D. Griffin, A. H. Sharpe, and J. A. Bluestone. 1999. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J. Immunol. 162:5784.
44. Oosterwegel, M. A., D. A. Mandelbrot, S. D. Boyd, R. B. Lorsbach, D. Y. Jarrett, A. K. Abbas, and A. H. Sharpe. 1999. The role of CTLA-4 in regulating Th2 differentiation. J. Immunol. 163:2634.
45. Sethna, M. P., L. van Parijs, A. H. Sharpe, A. K. Abbas, and G. J. Freeman. 1994. A negative regulatory function of B7 revealed in B7-1 transgenic mice. Immunity 1:415.
46. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155:1032.
47. Gause, W. C., M. J. Halvorson, P. Lu, R. Greenwald, P. Linsley, J. F. Urban, and F. D. Finkelman. 1997. The function of costimulatory molecules and the development of IL-4-producing T cells. Immunol. Today 18:115.
48. Schuler, T., Z. Qin, S. Ibe, N. Noben-Trauth, and T. Blankenstein. 1999. T helper cell type 1 -associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J. Exp. Med. 189:803.
49. + T-cell responses in mice homozygous for disruption of the interleukin-4 gene J. Virol. 71:2518.
50. + T helper type 1 cell responses to Candida albicans. J. Exp. Med. 187:307.
51. Kaufmann, S. H. E., M. Emoto, G. Szalay, J. Barsig, and I. E. A. Flesch. 1997. Interleukin-4 and listeriosis [Review]. Immunol. Rev. 158:95.
52. Liu, Y., and C. A. Janeway, Jr. 1990. Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J. Exp. Med. 172:1735.
53. Novelli, F., M. M. D'Elios, P. Bernabei, L. Ozmen, L. Rigamonti, F. Almerigogna, G. Forni, and G. Del Prete. 1997. Expression and role in apoptosis of the α- and β-chains of the IFN-γ receptor on human Th1 and Th2 clones. J. Immunol. 159:206.
54. Lanier, L. L., S. O'Fallon, C. Somoza, J. H. Phillips, P. S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154:97.
55. Natesan, M., Z. Razi-Wolf, and H. Reiser. 1996. Costimulation of IL-4 production by murine B7-1 and B7-2 molecules. J. Immunol. 156:2783.
56. Greenwald, R. J., P. Lu, M. J. Halvorson, X. Zhou, S. Chen, K. B. Madden, P. J. Perrin, S. C. Morris, F. D. Finkelman, R. Peach, et al. 1997. Effects of blocking B7-1 and B7-2 interactions during a type 2 in vivo immune response. J. Immunol. 158:4088.
57. + T cells by B7-transfected melanoma cells. Science 259:368.
58. Novelli, F., P. Bernabei, L. Ozmen, L. Rigamonti, A. Allione, S. Pestka, G. Garotta, and G. Forni. 1996. Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-γ is correlated with the differential expression of the α- and β-chains of its receptor. J. Immunol. 157:1935.